(TFX) Teleflex - Overview
Stock: Catheters, Balloon Pumps, Vascular Closure, Urology Devices, Respiratory Aids
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 1.11% |
| Yield on Cost 5y | 0.35% |
| Yield CAGR 5y | 0.00% |
| Payout Consistency | 95.4% |
| Payout Ratio | 13.2% |
| Risk 5d forecast | |
|---|---|
| Volatility | 33.9% |
| Relative Tail Risk | -17.1% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -1.02 |
| Alpha | -50.60 |
| Character TTM | |
|---|---|
| Beta | 0.785 |
| Beta Downside | 0.863 |
| Drawdowns 3y | |
|---|---|
| Max DD | 62.52% |
| CAGR/Max DD | -0.39 |
Description: TFX Teleflex January 08, 2026
Teleflex Incorporated (NYSE: TFX) designs, develops, manufactures, and supplies a broad portfolio of single-use medical devices used in critical-care and surgical settings worldwide. Its product suite spans vascular access (Arrow catheters, intra-osseous systems), interventional tools (coronary catheters, mechanical circulatory-support platforms, intra-aortic balloon pumps), anesthesia and hemostasis solutions, laparoscopic and percutaneous surgical instruments, urology technologies (UroLift System), respiratory care devices, and OEM components for other manufacturers.
In FY 2023 the company generated roughly **$2.6 billion** in revenue, with an operating margin of **≈13 %** and diluted EPS of **$3.70**. Teleflex paid a quarterly dividend of **$0.31 per share** (≈1.5 % yield) and posted free cash flow of about **$500 million**, supporting its ongoing share-repurchase program and incremental acquisitions.
Key macro-drivers for Teleflex include the continued shift toward minimally invasive procedures, an aging U.S. and global population that expands demand for vascular and urologic therapies, and hospital cost-containment pressures that favor single-use, cost-predictable devices. The health-care equipment sector’s average revenue growth of **≈6 % CAGR** over the past five years provides a favorable backdrop for Teleflex’s product-line diversification.
For a deeper dive into Teleflex’s valuation metrics and peer comparison, the ValueRay platform offers a concise, data-rich overview.
Piotroski VR‑10 (Strict, 0-10) 4.5
| Net Income: -328.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.03 > 0.02 and ΔFCF/TA -2.65 > 1.0 |
| NWC/Revenue: 38.02% < 20% (prev 29.10%; Δ 8.92% < -1%) |
| CFO/TA 0.05 > 3% & CFO 390.9m > Net Income -328.0m |
| Net Debt (2.42b) to EBITDA (58.1m): 41.56 < 3 |
| Current Ratio: 2.57 > 1.5 & < 3 |
| Outstanding Shares: last quarter (44.2m) vs 12m ago -5.90% < -2% |
| Gross Margin: 53.67% > 18% (prev 0.56%; Δ 5311 % > 0.5%) |
| Asset Turnover: 41.54% > 50% (prev 40.42%; Δ 1.12% > 0%) |
| Interest Coverage Ratio: -2.33 > 6 (EBITDA TTM 58.1m / Interest Expense TTM 96.5m) |
Altman Z'' 3.37
| A: 0.15 (Total Current Assets 1.99b - Total Current Liabilities 773.0m) / Total Assets 7.87b |
| B: 0.49 (Retained Earnings 3.88b / Total Assets 7.87b) |
| C: -0.03 (EBIT TTM -224.6m / Avg Total Assets 7.68b) |
| D: 0.90 (Book Value of Equity 3.66b / Total Liabilities 4.05b) |
| Altman-Z'' Score: 3.37 = A |
Beneish M -2.94
| DSRI: 1.20 (Receivables 592.7m/470.3m, Revenue 3.19b/3.03b) |
| GMI: 1.04 (GM 53.67% / 55.99%) |
| AQI: 0.90 (AQ_t 0.65 / AQ_t-1 0.72) |
| SGI: 1.05 (Revenue 3.19b / 3.03b) |
| TATA: -0.09 (NI -328.0m - CFO 390.9m) / TA 7.87b) |
| Beneish M-Score: -2.94 (Cap -4..+1) = A |
What is the price of TFX shares?
Over the past week, the price has changed by +0.39%, over one month by -14.92%, over three months by -14.85% and over the past year by -39.18%.
Is TFX a buy, sell or hold?
- StrongBuy: 0
- Buy: 2
- Hold: 11
- Sell: 1
- StrongSell: 0
What are the forecasts/targets for the TFX price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 129.3 | 22.1% |
| Analysts Target Price | 129.3 | 22.1% |
| ValueRay Target Price | 83.6 | -21.1% |
TFX Fundamental Data Overview February 03, 2026
P/S = 1.446
P/B = 1.2197
P/EG = 0.1641
Revenue TTM = 3.19b USD
EBIT TTM = -224.6m USD
EBITDA TTM = 58.1m USD
Long Term Debt = 2.57b USD (from longTermDebt, last quarter)
Short Term Debt = 100.0m USD (from shortTermDebt, last quarter)
Debt = 2.77b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 2.42b USD (from netDebt column, last quarter)
Enterprise Value = 7.03b USD (4.61b + Debt 2.77b - CCE 354.0m)
Interest Coverage Ratio = -2.33 (Ebit TTM -224.6m / Interest Expense TTM 96.5m)
EV/FCF = 26.59x (Enterprise Value 7.03b / FCF TTM 264.3m)
FCF Yield = 3.76% (FCF TTM 264.3m / Enterprise Value 7.03b)
FCF Margin = 8.29% (FCF TTM 264.3m / Revenue TTM 3.19b)
Net Margin = -10.28% (Net Income TTM -328.0m / Revenue TTM 3.19b)
Gross Margin = 53.67% ((Revenue TTM 3.19b - Cost of Revenue TTM 1.48b) / Revenue TTM)
Gross Margin QoQ = 49.47% (prev 55.20%)
Tobins Q-Ratio = 0.89 (Enterprise Value 7.03b / Total Assets 7.87b)
Interest Expense / Debt = 1.36% (Interest Expense 37.6m / Debt 2.77b)
Taxrate = 7.04% (5.32m / 75.5m)
NOPAT = -208.8m (EBIT -224.6m * (1 - 7.04%)) [loss with tax shield]
Current Ratio = 2.57 (Total Current Assets 1.99b / Total Current Liabilities 773.0m)
Debt / Equity = 0.72 (Debt 2.77b / totalStockholderEquity, last quarter 3.82b)
Debt / EBITDA = 41.56 (Net Debt 2.42b / EBITDA 58.1m)
Debt / FCF = 9.14 (Net Debt 2.42b / FCF TTM 264.3m)
Total Stockholder Equity = 4.11b (last 4 quarters mean from totalStockholderEquity)
RoA = -4.27% (Net Income -328.0m / Total Assets 7.87b)
RoE = -7.98% (Net Income TTM -328.0m / Total Stockholder Equity 4.11b)
RoCE = -3.36% (EBIT -224.6m / Capital Employed (Equity 4.11b + L.T.Debt 2.57b))
RoIC = -3.40% (negative operating profit) (NOPAT -208.8m / Invested Capital 6.14b)
WACC = 5.98% (E(4.61b)/V(7.38b) * Re(8.81%) + D(2.77b)/V(7.38b) * Rd(1.36%) * (1-Tc(0.07)))
Discount Rate = 8.81% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -3.29%
[DCF Debug] Terminal Value 86.59% ; FCFF base≈338.6m ; Y1≈359.2m ; Y5≈427.9m
Fair Price DCF = 224.9 (EV 12.36b - Net Debt 2.42b = Equity 9.94b / Shares 44.2m; r=5.98% [WACC]; 5y FCF grow 6.72% → 2.90% )
EPS Correlation: -35.05 | EPS CAGR: -45.09% | SUE: -4.0 | # QB: 0
Revenue Correlation: 62.45 | Revenue CAGR: 4.94% | SUE: 1.33 | # QB: 1
EPS next Quarter (2026-03-31): EPS=3.11 | Chg30d=-0.010 | Revisions Net=+0 | Analysts=7
EPS next Year (2026-12-31): EPS=15.21 | Chg30d=+0.011 | Revisions Net=-3 | Growth EPS=+8.5% | Growth Revenue=+11.0%